Itai Levi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Itai Levi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Itamar Grotto
School of Public Health, Ben-Gurion University of the Negev, Be'er Sheva, Israel
2 shared publications A. Polliack
Department of Hematology, Hadassah University Hospital, Hebrew University Medical School, Jerusalem, Israel
1 shared publication- Alex Rabinovich
Thrombosis and Hemostasis unit, Hematology institute, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
1 shared publication - Anatoly Nemets
Barzilai Medical Center, Ashkelon 78306, Israel
1 shared publication - Baher Krayem
Rambam Health Care Campus, Haifa 3109601, Israel
1 shared publication - Dally Najib
Ziv Medical Center, Bar-Ilan University, Zefad 5290002, Israel
1 shared publication
Latest Publications
- Open Access
- 9 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5865
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level
Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent). The anemia subgroups were: none/normal (Hb ≥ 12.5 g/dL), mild (10 ≤ Hb < 12.5), moderate (9 ≤ Hb < 10), severe (8 ≤ Hb < 9), or very severe (Hb < 8). LR-MDS patients (n = 127) and inpatient controls (n = 141) participated. The anemic patients had a poor QoL and the MDS patients had a lower QoL with a lower Hb. The controls had no QoL difference among the various anemia subgroups. In addition, the MDS QoL sharply decreased with an Hb of < 9. The MDS patients showed a wide QoL variability, i.e., different QoL scores in the same Hb subgroup, suggesting that other factors affect QoL (e.g., age and comorbidities). After 1 year (n = 61), the QoL was still poor for most MDS patients (including 27 patients with an increased Hb). In summary: (1) a poor QoL in MDS-anemia is non-linear, suggesting other influencing factors on QoL. (2) The sharp QoL drop with Hb < 9 g/dL challenges the transfusion Hb threshold. (3) The QoL in anemic MDS patients might differ from that in non-MDS patients. (4) Raising Hb, while recommended, does not guarantee an improved QoL.
- 9 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5865
Open AccessMDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level
Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent). The anemia subgroups were: none/normal (Hb ≥ 12.5 g/dL), mild (10 ≤ Hb < 12.5), moderate (9 ≤ Hb < 10), severe (8 ≤ Hb < 9), or very severe (Hb < 8). LR-MDS patients (n = 127) and inpatient controls (n = 141) participated. The anemic patients had a poor QoL and the MDS patients had a lower QoL with a lower Hb. The controls had no QoL difference among the various anemia subgroups. In addition, the MDS QoL sharply decreased with an Hb of < 9. The MDS patients showed a wide QoL variability, i.e., different QoL scores in the same Hb subgroup, suggesting that other factors affect QoL (e.g., age and comorbidities). After 1 year (n = 61), the QoL was still poor for most MDS patients (including 27 patients with an increased Hb). In summary: (1) a poor QoL in MDS-anemia is non-linear, suggesting other influencing factors on QoL. (2) The sharp QoL drop with Hb < 9 g/dL challenges the transfusion Hb threshold. (3) The QoL in anemic MDS patients might differ from that in non-MDS patients. (4) Raising Hb, while recommended, does not guarantee an improved QoL.
- Open Access
- 16 December 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 672
Clinical and epidemiologic characteristics of non Hodgkin’s lymphoma in Bedouins in the south of Israel
The presentation of Non Hodgkin’s Lymphoma (NHL) may vary in relation to ethnicity or environmental effects. The objective of our study was to characterize NHL among the Negev Bedouin population, compared to the Jewish population. Retrospective data were collected for 45 Bedouin and 45 Jewish patients who were treated at Soroka University Medical Center between 1990 and 2007. Upon diagnosis, rates of aggressive NHL types, involvement of extra-lymphatic organs, as well as mean LDH were higher among Bedouin. Treatment response was poorer among the Bedouin: overall survival and disease-free survival were higher among Jews (mean of 145 and 168 months, respectively, compared with 70 and 45 months, respectively, among Bedouin; p < 0.01 for both). In summary, disease aggressiveness and poor response to treatment among the Negev Bedouin may shed some light on the pathogenicity of NHL and may indicate a need for more aggressive treatment in different ethnic groups.
- 16 December 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 672
Open AccessClinical and epidemiologic characteristics of non Hodgkin’s lymphoma in Bedouins in the south of Israel
The presentation of Non Hodgkin’s Lymphoma (NHL) may vary in relation to ethnicity or environmental effects. The objective of our study was to characterize NHL among the Negev Bedouin population, compared to the Jewish population. Retrospective data were collected for 45 Bedouin and 45 Jewish patients who were treated at Soroka University Medical Center between 1990 and 2007. Upon diagnosis, rates of aggressive NHL types, involvement of extra-lymphatic organs, as well as mean LDH were higher among Bedouin. Treatment response was poorer among the Bedouin: overall survival and disease-free survival were higher among Jews (mean of 145 and 168 months, respectively, compared with 70 and 45 months, respectively, among Bedouin; p < 0.01 for both). In summary, disease aggressiveness and poor response to treatment among the Negev Bedouin may shed some light on the pathogenicity of NHL and may indicate a need for more aggressive treatment in different ethnic groups.
- 5 October 2011
- Published by Elsevier in Leukemia Research
- Vol. 36 (1) , 42-45
Clomiphene as a novel modality for the treatment of acute myeloid leukemia: A pilot phase II study
- 5 October 2011
- Published by Elsevier in Leukemia Research
- Vol. 36 (1) , 42-45
Clomiphene as a novel modality for the treatment of acute myeloid leukemia: A pilot phase II study
- 1 June 2004
- Published by Elsevier in Leukemia Research
- Vol. 28 (6) , 605-612
Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission
- 1 June 2004
- Published by Elsevier in Leukemia Research
- Vol. 28 (6) , 605-612
Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission